MedTrace Logo

A Prospective Study on the Application of Liquid Biopsy in the Surveillance of High-risk Population of HCC.

NCT06134973 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2023-11-22

No results posted yet for this study

Summary

Liquid biopsy technology based on high-throughput sequencing can detect trace signals in the early stage of cancer in plasma free DNA, so it has become a new technology suitable for tumor diagnosis and screening.Relying on the key discipline of digestive liver disease in our hospital, this project cooperated with BGI to jointly carry out a prospective study on the application of liquid biopsy in the monitoring of population at risk of liver cancer by taking advantage of its technical advantages in next-generation sequencing, so as to provide an innovative way for the prevention and treatment of Hepatocellular Carcinoma.

Conditions

Interventions

DIAGNOSTIC_TEST

ultrasonic testing

ultrasonic testing

Sponsors & Collaborators

  • BGI, China

    collaborator OTHER

  • Tianjin Third Central Hospital

    lead OTHER

Principal Investigators

  • Fengmei Wang, PhD · Tianjin Third Central Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-01
Primary Completion
2025-06-30
Completion
2025-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06134973 on ClinicalTrials.gov